CTOs on the Move

New York Cancer and Blood Specialists

www.nycancer.com

 
New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.nycancer.com
  • 1500 Route 112 Building 4
    Port Jefferson Station, NY USA 11776
  • Phone: 631.751.3000

Executives

Name Title Contact Details
Carlos Ng
Vice President of Information Technology Profile
Sean Riley
Chief Information Officer Profile

Similar Companies

Horizon Therapeutics

At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Neopharm Labs

As a trusted partner to leaders in the pharmaceutical and life sciences industry for over 30 years, we`ve built a reputation for quality, problem‑solving capabilities, and a superior customer experience. We`re proud to play an integral role in bettering the lives of the global community.

Butterfield's Pharmacy and Medical Supplies

Butterfield's Pharmacy and Medical Supplies is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epic Technology Consulting

Epic Technology Consulting is a Villa Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.